Actelion Stock Xetra

Stocks

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
10/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
10/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	+2.35%	+0.77%	+29.92%	+85.38%	55.23B
ARGENX SE	-0.21%	-6.52%	+42.39%	+64.10%	53.75B
BIONTECH SE	-2.44%	-1.61%	-17.69%	-15.68%	23.48B
INSMED INCORPORATED	-2.85%	-8.20%	-6.26%	+361.83%	22B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-1.27%	+15.99%	-10.53%	19.78B
GENMAB A/S	+0.79%	-2.39%	+26.99%	-31.34%	17.44B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-7.23%	+24.50%	+519.07%	14.66B
EXELIXIS, INC.	-5.25%	-4.71%	+43.89%	+167.15%	14.07B
PHARMAESSENTIA CORPORATION	+3.41%	-7.83%	+161.76%	+284.91%	13.02B
Average	-0.11%	-1.43%	+35.72%	+158.32%	25.94B
Weighted average by Cap.	+0.17%	+0.09%	+31.05%	+122.81%